# Galcanezumab

## Emgality inj 120 mg/1mL

##### 臨採

| TAH Drug Code      | [IEMG](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IEMG)                                                                                                                                                                                            |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Preventing Migraines in adults.                                                                                                                                                                                                                                 |
| Dosing             | Migraine; Prophylaxis Usual dosage: 240 mg (2 consecutive 120-mg doses) once as a loading dose, followed by 120 mg once monthly. Missed dose: If a dose is missed, administer as soon as possible. Thereafter, schedule monthly from the date of the last dose. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                   |
| Contraindications  | Serious hypersensitivity to galcanezumab-gnlm or to any of the components of the product.                                                                                                                                                                       |
| Adverse Effects    | Common Immunologic: Injection site reaction (18% ) Serious Immunologic: Anaphylaxis, Hypersensitivity reaction Other: Angioedema                                                                                                                                |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/galcanezumab-drug-information)                                                                                                                                                                                     |

